CD22 Inhibitors
1 drugsAbout CD22
CD22 is a B-cell specific transmembrane sialoglycoprotein receptor modulating B-cell receptor signaling. Primarily expressed on mature B lymphocytes, it regulates B-cell activation and tolerance.
CD22 is an attractive target for therapeutic intervention, particularly in B-cell malignancies. Currently, there is no genetic evidence data available linking CD22 to specific diseases.
CD22 is targeted by one FDA-approved drug, BESPONSA, an antibody-drug conjugate (ADC) used in oncology. Pfizer is the primary company in this space.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Central Nervous System Leukemia with only 1 trials.
- phase2 represents biological uncertainty with 33% completion.
Top Drugs
Pfizer is the leading company with an approved drug targeting CD22.
High market concentration suggests significant entry barriers; strategic partnerships may be beneficial.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CD22, using adc modality.
Explore alternative modalities to differentiate from existing therapies and expand market reach.
Clinical Trials 70 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 24 | 14 | 1 | 9 | 93% |
| Phase 2 | 29 | 7 | 4 | 17 | 64% |
| Phase 3 | 12 | 4 | 3 | 5 | 57% |
| Phase 4 | 5 | 4 | 1 | 0 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2017 - 2017)
BESPONSA was first approved in 2017 and remains the only approved drug.
Limited approval history indicates potential for new entrants, but also a risk of target saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 51 clinical trials targeting CD22.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities